Close Menu

NEW YORK (360Dx) – Cancer detection firm Oncimmune announced on Tuesday that it has signed a licensing agreement for its EarlyCDT autoantibody-based diagnostics platform in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.